AU2010295717B2 - ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases - Google Patents

ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases Download PDF

Info

Publication number
AU2010295717B2
AU2010295717B2 AU2010295717A AU2010295717A AU2010295717B2 AU 2010295717 B2 AU2010295717 B2 AU 2010295717B2 AU 2010295717 A AU2010295717 A AU 2010295717A AU 2010295717 A AU2010295717 A AU 2010295717A AU 2010295717 B2 AU2010295717 B2 AU 2010295717B2
Authority
AU
Australia
Prior art keywords
cancer
abt
compound
free base
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010295717A
Other languages
English (en)
Other versions
AU2010295717A1 (en
Inventor
Thomas B. Borchardt
Paul J. Brackemeyer
Nathaniel D. Catron
Geoff G.Z Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2010295717A1 publication Critical patent/AU2010295717A1/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. Request for Assignment Assignors: ABBOTT LABORATORIES
Application granted granted Critical
Publication of AU2010295717B2 publication Critical patent/AU2010295717B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010295717A 2009-09-20 2010-09-15 ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases Ceased AU2010295717B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
US61/244,051 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Publications (2)

Publication Number Publication Date
AU2010295717A1 AU2010295717A1 (en) 2012-03-22
AU2010295717B2 true AU2010295717B2 (en) 2014-09-11

Family

ID=43064468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010295717A Ceased AU2010295717B2 (en) 2009-09-20 2010-09-15 ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases

Country Status (15)

Country Link
US (2) US8362014B2 (enExample)
EP (1) EP2477972A1 (enExample)
JP (2) JP2013505249A (enExample)
KR (1) KR20120085781A (enExample)
CN (2) CN102695702A (enExample)
AU (1) AU2010295717B2 (enExample)
BR (1) BR112012006252A2 (enExample)
CA (1) CA2771984A1 (enExample)
IL (1) IL218403A0 (enExample)
MX (1) MX2012003408A (enExample)
NZ (1) NZ598461A (enExample)
RU (1) RU2551376C2 (enExample)
TW (1) TWI488853B (enExample)
WO (1) WO2011034934A1 (enExample)
ZA (1) ZA201202891B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106390114A (zh) * 2008-11-07 2017-02-15 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
HRP20151168T1 (hr) * 2008-11-07 2015-12-04 Amgen Research (Munich) Gmbh Lijeäśenje akutne limfoblastiäśne leukemije
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
CN102695702A (zh) 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
EP2515883A4 (en) * 2009-12-22 2013-07-17 Abbvie Inc CAPSULE OF ABT-263
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AU2014220354B2 (en) * 2013-02-21 2018-02-01 Pfizer Inc. Solid forms of a selective CDK4/6 inhibitor
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
EP2988767A1 (en) * 2013-04-21 2016-03-02 Yeda Research and Development Co., Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
EP3076977B1 (en) * 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
SG11201606239UA (en) * 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015157120A1 (en) * 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
JP7417356B2 (ja) 2019-01-25 2024-01-18 株式会社ソニー・インタラクティブエンタテインメント ロボット制御システム
WO2021092030A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters
WO2009155386A1 (en) * 2008-06-20 2009-12-23 Abbott Laboratories A process for the preparation of the apoptosis promoter abt-263

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
JP4202380B2 (ja) * 2006-10-17 2008-12-24 シャープ株式会社 画像形成装置
JP2011506338A (ja) * 2007-12-06 2011-03-03 アボット・ラボラトリーズ 癌の治療のためのａｂｔ−２６３の経口用組成物
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2010259520A (ja) * 2009-04-30 2010-11-18 Motoji Ono 搬送機構、トレッドミル及びコンベア
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
CN102695702A (zh) 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN101798292A (zh) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027135A1 (en) * 2005-05-12 2007-02-01 Milan Bruncko Apoptosis promoters
WO2009155386A1 (en) * 2008-06-20 2009-12-23 Abbott Laboratories A process for the preparation of the apoptosis promoter abt-263

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARK, C., et al., Journal of Medicinal Chemistry, 2008, Vol. 51, pages 6902-6915 *
WANG, G., et al., Synthesis, 2008, (15), Pages 2398-2404 *

Also Published As

Publication number Publication date
TW201116526A (en) 2011-05-16
IL218403A0 (en) 2012-04-30
KR20120085781A (ko) 2012-08-01
US20110071151A1 (en) 2011-03-24
BR112012006252A2 (pt) 2017-05-23
NZ598461A (en) 2013-12-20
JP2013505249A (ja) 2013-02-14
US20110294811A1 (en) 2011-12-01
CN105820138A (zh) 2016-08-03
RU2012115851A (ru) 2013-10-27
JP2015232006A (ja) 2015-12-24
CA2771984A1 (en) 2011-03-24
US8362014B2 (en) 2013-01-29
TWI488853B (zh) 2015-06-21
US8513243B2 (en) 2013-08-20
WO2011034934A1 (en) 2011-03-24
RU2551376C2 (ru) 2015-05-20
ZA201202891B (en) 2013-09-25
AU2010295717A1 (en) 2012-03-22
CN102695702A (zh) 2012-09-26
EP2477972A1 (en) 2012-07-25
MX2012003408A (es) 2012-08-03

Similar Documents

Publication Publication Date Title
US8513243B2 (en) ABT-263 crystalline forms
US8362013B2 (en) Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) Solid oral formulation of abt-263
US8728516B2 (en) Stabilized lipid formulation of apoptosis promoter
AU2010336518B2 (en) ABT-263 capsule
US20230183236A1 (en) Crystalline forms of an apoptosis-inducing agent

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE INC.

Free format text: FORMER APPLICANT(S): ABBOTT LABORATORIES

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired